At Mezzion, we have one simple goal: to build a better future for people living with single ventricle heart disease and Fontan circulation. Adolescents and young adults with Fontan circulation face a major obstacle in their long-term health journey—nearly all the innovation in the congenital heart disease space, including surgical options, is unfortunately behind them. What lies ahead is uncertainty for what their future holds; what life in their 20’s, 30’s and beyond will look like and what limitations they will face. 

We want to ensure that the future is clear and bright and the limitations minimal, because innovation for Fontan patients must continue beyond infancy and childhood. Mezzion has been on a 20+ year journey into the globally competitive research, development, and manufacturing company that we are today. Though there are challenges and setbacks for a company like ours researching and innovating in the rare disease space, investment in our science is strong, and we are well positioned to help Fontan patients live longer, healthier lives with their native hearts. 

I am incredibly confident about our pipeline and what it will hold for Fontan patients. I want to thank all those who have supported our vision and our science throughout the years.

Sincerely,
Dean Park
CEO, Mezzion